Composition Of Skin External Application For Anti-Aging

Abstract

The present invention relates to an anti-aging composition for external use on skin, and more particularly, to an anti-aging composition for external use on skin comprising at least one of catechins and flavonols as an active ingredient to inhibit decomposition and promote generation or protection at the dermis-epidermis junction.

1 . An anti-aging composition for external use on skin comprising at least one of catechins and flavonols as an active ingredient. 
   
   
       2 . The composition according to  claim 1 , wherein the catechins are selected from the group consisting of (−)EGCG (epigallocatechin gallate), (−)GCG (gallocatechin gallate), (−)ECG (epicatechin gallate), (−)CG (catechin gallate), (−)EGC (epigallocatechin), (−)GC (gallocatechin), (−)EC (epicatechin), (+)EC (epicatechin), (−)CA (catechin) and (+)CA (catechin). 
   
   
       3 . The composition according to  claim 1 , wherein the flavonols are selected from the group consisting of quercetin, kaempferol and myricetin. 
   
   
       4 . The composition according to  claim 1 , wherein the active ingredient is contained in an amount of 0.001 to 10 wt %, based on the total weight of the composition. 
   
   
       5 . The composition according to  claim 1 , which further comprises theanine as an active ingredient. 
   
   
       6 . The composition according to  claim 5 , which comprises 0.004 to 0.025 wt %, based on the total weight of the composition, of at least one of catechins and flavonols and 0.008 to 2.5 wt %, based on the total weight of the composition, of theanine, in which the content ratio of the at least one of catechins and flavonols to theanine is 1:20 to 1:100. 
   
   
       7 . A method of promoting biosynthesis of collagen comprising administering to a subject the composition of  claim 1 . 
   
   
       8 . A method of reducing wrinkles comprising administering to a subject the composition of  claim 1 . 
   
   
       9 . A method of improving skin elasticity comprising administering to a subject the composition of  claim 1 . 
   
   
       10 . A method of activating peroxisome proliferator-activated receptors-alpha (PPAR-α) comprising administering to a subject the composition of  claim 1 . 
   
   
       11 . A method of inhibiting inflammation comprising administering to a subject the composition of  claim 1 . 
   
   
       12 . A method of inhibiting expression of MMP-1 comprising administering to a subject the composition of  claim 1 . 
   
   
       13 . A method of inhibiting tumor necrosis factor α (TNF-α) comprising administering to a subject the composition of  claim 1 .